// App-Quantinova.ai

TPS9109 : GEOMETRY duo-1: A phase (Ph) Ib/II, multicenter trial of oral cMET inhibitor capmatinib (INC280) erlotinib vs platinum + pemetrexed in adult patients (pts) with epidermal growth factor receptor (EGFR)-mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy.

Researchers

Presenter

  • Egbert F. Smit

Principal Investigators

  • Hans-Georg Kopp

  • Dong-Wan Kim

  • Giampaolo Tortora

  • Alexander I. Spira

  • Alfredo Berruti

  • Dae Ho Lee

  • Noemi Reguart

  • Igor I. Rybkin

  • Mikhail Akimov

  • Karl Maria Schumacher

  • Allison Upalawanna

  • Cindy Xu

  • Matthew Squires

  • Daniel Shao-Weng Tan

Medical Centers

  • VU University Medical Center, Amsterdam, Netherlands

  • Department of Oncology and Hematology, Comprehensive Cancer Center, Tuebingen, Germany

  • Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy

  • Virginia Cancer Specialists Research Institute, and Oncology Research, Fairfax, VA

  • Azienda Ospedaliera Spedali Civili di Brescia, University of Brescia, Brescia, Italy

  • University Hospital Clinic of Barcelona, Barcelona, Spain

  • Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, MI

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • National Cancer Centre Singapore, Singapore, Singapore

Locations

  • Italy

  • Netherlands

  • Singapore

  • Germany

  • Spain

  • Switzerland

  • United States

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Carboplatin

  • Capmatinib

  • Pemetrexed

  • Erlotinib hydrochloride

  • Cisplatin

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Multicenteric

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT02468661

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved